References of "Evenepoel, Pieter"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailSclerostin and chronic kidney disease: the assay impacts what we (thought to) know.
DELANAYE, Pierre ULiege; PAQUOT, Francois ULiege; BOUQUEGNEAU, Antoine ULiege et al

in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2017)

Background: Sclerostin, a 22-kDa protein secreted by osteocytes, acts as a potent inhibitor of osteoblast activity. In chronic kidney disease (CKD), sclerostin is a putative driver of the bone-vascular ... [more ▼]

Background: Sclerostin, a 22-kDa protein secreted by osteocytes, acts as a potent inhibitor of osteoblast activity. In chronic kidney disease (CKD), sclerostin is a putative driver of the bone-vascular axis. However, large discrepancies between sclerostin assays have been described. Methods: We compared four different assays [Biomedica (BM), TecoMedical (TE), R&D (RD) and MesoScaleDiscovery (MSD)] in an analytical study and addressed the question whether bioassay choice affects the correlation between circulating sclerostin and clinical and biochemical determinants. Circulating sclerostin levels were determined in 39 prevalent dialysis patients and 82 non-dialysis patients referred for glomerular filtration rate measurement. Results: In the 82 non-dialysis patients, we observed large differences in median (interquartile range) sclerostin concentrations (in pg/mL): BM, 984 [interquartile range (IQR) 648]; TE, 629 (IQR 237); RD, 154 (IQR 84) and MSD, 36 (IQR 19). The concordance correlation coefficient between assays was poor (0.1-0.44). The same discrepancies were observed in dialysis patients. A significant negative rank correlation was found between glomerular filtration rate and sclerostin measured by BM and TE but not by MSD and RD. Associations between sclerostin and age, gender, weight or parathormone were also different according to the assay considered. Conclusions: Clinical inference relating sclerostin levels found in the general, CKD and dialysis populations is largely influenced by the assay used to measure this biomarker. [less ▲]

Detailed reference viewed: 14 (0 ULiège)
Full Text
Peer Reviewed
See detailBiomarkers Predicting Bone Turnover in the Setting of CKD.
Evenepoel, Pieter; Cavalier, Etienne ULiege; D'Haese, Patrick C.

in Current Osteoporosis Reports (2017)

PURPOSE OF THE REVIEW: Impaired bone quality contributes to the increased fracture risk in chronic kidney disease patients. Both low and high turnover bone disease may compromise bone quality. The ... [more ▼]

PURPOSE OF THE REVIEW: Impaired bone quality contributes to the increased fracture risk in chronic kidney disease patients. Both low and high turnover bone disease may compromise bone quality. The question arises whether bone biomarkers may be additive or replace bone histormorphometry for diagnosing the extremes of bone turnover. RECENT FINDINGS: Studies exploring the performance of established and emerging bone biomarkers against histomorphometric assessment of bone turnover are limited and overall yield inconclusive results as to their diagnostic utility. Bone biomarkers, although promising, currently fail to meet the needed diagnostic accuracy to replace bone histomorphometry and thus are not yet ready for clinical use. Bone biomarkers have not only several advantages, but also important limitations such as high biological variability, retention with kidney disease, preanalytical issues, and interassay variability. These important issues must be considered when developing and evaluating bone biomarkers. There is an urgent need for harmonization and standardization of available assays and additional bone biopsy studies. [less ▲]

Detailed reference viewed: 10 (1 ULiège)
Full Text
See detailPeut-on prédire la mortalité cardiovasculaire chez les patients en dialyse? Les enseignements, présents et à venir, de l'étude CORD
Krzesinski, Jean-Marie ULiege; Jadoul, Michel; Evenepoel, Pieter et al

in Tempo Medical (2009)

Les patients hémodialysés sont exposés à un risque cardiovasculaire accru et les calcifications vasculaires sont considérées comme un marqueur de cette augmentation de risque. L'étude CORD (Calcification ... [more ▼]

Les patients hémodialysés sont exposés à un risque cardiovasculaire accru et les calcifications vasculaires sont considérées comme un marqueur de cette augmentation de risque. L'étude CORD (Calcification Outcome in Renal Disease) revêt dès lors un intérêt particulier. Elle vise initialement à déterminer la prévalence et la sévérité des calcifications de l'aorte abdominale chez les patients dialysés et à identifier les facteurs prédictifs de ces calcifications. Elle ouvre également des perspectives importantes en matière de prévention et d'attitude thérapeutique. Quatre experts nous livrent leurs commentaires à ce propos. [less ▲]

Detailed reference viewed: 66 (4 ULiège)